Improving quality of life through innovations in urology.
Urovant Sciences
Vibegron
Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).
Latest News
The latest posts and articles
-
Urovant Sciences to Ring the Nasdaq Stock...
on January 17, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Jan. 17, 2020-- Urovant Sciences […]
Read Latest Post -
Urovant Sciences to Present at the 38th...
on January 8, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Jan. 8, 2020-- Urovant Sciences (Nasdaq: […]
Read Latest Post -
Urovant Sciences Announces Submission of New...
on December 30, 2019
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Dec. 30, 2019-- Urovant Sciences […]
Read Latest Post
View more
Copyright 2018 © All Rights Reserved